Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synflorix + Infanrix hexa + Rotarix
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
Synflorix + Infanrix hexa + Rotarix is a co-administered vaccine regimen developed by GlaxoSmithKline (GSK) for routine infant immunization. This combination provides broad protection against eight major pediatric pathogens. **Infanrix hexa** is a hexavalent vaccine protecting against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and *Haemophilus influenzae* type b. **Synflorix** is a 10-valent pneumococcal conjugate vaccine (PCV-10) targeting ten serotypes of *Streptococcus pneumoniae*. **Rotarix** is a monovalent, live attenuated oral vaccine designed to prevent rotavirus gastroenteritis. These vaccines are typically administered together at 2, 4, and 6 months of age (or similar schedules) to simplify the immunization process and ensure high coverage against life-threatening childhood infections.
- Other names
- Synflorix + Infanrix hexa + Rotarix co-administration
02
Targets
PRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on Synflorix + Infanrix hexa + Rotarix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synflorix + Infanrix hexa + Rotarix.